Tenpoint's $85M Bet on Retinal Regeneration

In a darkened lab, a cluster of human retinal cells, coaxed from a different fate, begins to respond to light. This is the quiet, foundational experiment at Tenpoint Therapeutics, a company built on the radical premise that lost vision can be restored not by replacing the eye's delicate photoreceptors, but by reprogramming neighboring cells to take their place. The company has now secured $85 million in venture funding to propel its lead candidate, TP-101, a gene therapy designed to convert Müller glial cells into functional photoreceptors, toward the clinic. Founded in 2024 by a cadre of retinal biologists and gene therapy veterans, Tenpoint is targeting degenerative diseases like retinitis pigmentosa and geographic atrophy, where the slow death of light-sensing rods and cones leads to irreversible blindness. Their approach sidesteps the immense surgical and immunological challenges of transplanting external cells, aiming instead to unlock the latent regenerative potential within the eye itself. This financing lands squarely in the midst of a renaissance for ocular gene therapies, moving beyond single-gene replacements to more complex regenerative and neuroprotective strategies. While competitors work on optogenetics or stem cell implants, Tenpoint is betting that in situ reprogramming offers a more elegant, durable solution. The new capital will fund IND-enabling studies for TP-101, with the goal of filing for its first clinical trial in late 2027, a milestone that could illuminate a new path for treating blindness.